On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...
Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...
Regeneron has bought Oxular ... due to enrol 18 patients in the US who have been previously treated with anti-VEGF therapy like Eylea to one of two dose levels of OXU-001. Part B will recruit ...
Hosted on MSN2mon
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent. Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration ...
Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications ...
The company revealed that those sales increased just 3% compared to the year earlier period, blaming "the lower net selling price compared to the third quarter of 2023" and "anti-VEGF category pricing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback